Home / Science / Scientific References / Inhibition of protein phosphatase-2A with LB-100 enhances…

2020 Jun;148(2):231-244. doi: 10.1007/s11060-020-03517-5. Epub 2020 Apr 27.

Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma

PMID: 32342332 PMCID: PMC7467059 DOI: 10.1007/s11060-020-03517-5


Purpose: Glioblastoma (GBM) carries a dismal prognosis despite standard multimodal treatment with surgery, chemotherapy and radiation. Immune checkpoint inhibitors, such as PD1 blockade, for treatment of GBM failed to show clinical benefit. Rational combination strategies to overcome resistance of GBM to checkpoint monotherapy are needed to extend the promise of immunotherapy to GBM management. Emerging evidence suggests that protein phosphatase 2A (PP2A) plays a critical role in the signal transduction pathways of both adaptive and innate immune cells and that inhibition of PP2A could enhance cancer immunity. We investigated the use of a PP2A inhibitor, LB-100, to enhance antitumor efficacy of PD1 blockade in a syngeneic glioma model.

Methods: C57BL/6 mice were implanted with murine glioma cell line GL261-luc or GL261-WT and randomized into 4 treatment arms: (i) control, (ii) LB-100, (iii) PD1 blockade and (iv) combination. Survival was assessed and detailed profiling of tumor infiltrating leukocytes was performed.

Results: Dual PP2A and PD1 blockade significantly improved survival compared with monotherapy alone. Combination therapy resulted in complete regression of tumors in about 25% of mice. This effect was dependent on CD4 and CD8 T cells and cured mice established antigen-specific secondary protective immunity. Analysis of tumor lymphocytes demonstrated enhanced CD8 infiltration and effector function.

Conclusion: This is the first preclinical investigation of the effect of combining PP2A inhibition with PD1 blockade for GBM. This novel combination provided effective tumor immunotherapy and long-term survival in our animal GBM model.

Keywords: GBM; Immunotherapy; LB-100; PP2A.

Conflict of interest statement

Conflict of interest: WH is a board member and has stock options for Lixte Biotechnology Holdings Inc. JK is a board member and own stocks for Lixte Biotechnology Holdings Inc. WH, HW, RL, JK, ZZ have pending patents related to this work. No potential conflicts of interest were disclosed by the other authors.